Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV a...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in nephrology 2016-01, Vol.2016 (2016), p.1-7
Main Authors: Visus-Fernández de Manzanos, María Teresa, de Álvaro Moreno, Fernando, Castillo Eraso, Lorena, Baltar Martín, José María, Quiroga, Borja, Peralta Roselló, Carmen, García Monteavaro, Camino, Martínez Vea, Alberto
Format: Article
Language:English
Subjects:
Anemia
Blood platelets
Case Report
Dehydrogenases
Haplotypes
Hemodialysis
Mutation
Nephrology
Patients
Proteins
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14±2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.
ISSN:2090-6641
2090-665X
DOI:10.1155/2016/7471082